Key Takeaways

  • Oncology real-world data (RWD) is becoming essential for clinical research, patient access and clinical outcomes improvement.
  • Privacy and GDPR compliance remain among the biggest barriers to unlocking the full value of healthcare data.
  • Traditional anonymization approaches struggle with the complexity of unstructured oncology data.
  • Danny Anonymization transforms raw patient records into research-ready, de-identified datasets – automatically and irreversibly.
  • Built specifically for clinical environments, it enables secure, scalable, and compliant data sharing for RWE, collaboration, and AI applications.
  • Clinical-grade anonymization is no longer just a compliance requirement – it is foundational infrastructure for modern oncology data ecosystems.

The Growing Importance of Oncology Real-World Data

Oncology is one of the most data-intensive and rapidly evolving fields in healthcare. Precision medicine, biomarker-driven therapies, combination treatments, and personalized patient pathways are transforming the way cancer care is delivered. At the same time, healthcare organizations are generating unprecedented volumes of clinical data through electronic health records (EHRs), pathology reports, imaging systems, genomic testing, and physician documentation.

This growing data landscape is fuelling the global demand for real-world evidence (RWE).

While clinical trials remain the gold standard for evaluating safety and efficacy, they cannot fully capture how therapies perform in diverse patient populations under real-world conditions. Trial populations are often narrowly defined, highly controlled, and limited in longitudinal follow-up.

Real-world oncology data helps bridge this gap by supporting:

  • treatment optimization
  • post-market surveillance
  • health technology assessment (HTA)
  • reimbursement strategies
  • long-term outcomes analysis
  • population-level research

However, the most valuable oncology data is often hidden inside complex, unstructured clinical records.

A medical report for a cancer patient, for example, may include:

  • patient names
  • dates of diagnosis
  • physician comments
  • rare disease references
  • location information
  • treatment history

Many of these identifiers are embedded within free-text narratives rather than structured database fields, making secure secondary use extremely difficult.

“Real-world oncology data is no longer optional – it is essential for evidence generation and decision-making.”

Why Privacy and GDPR Remain Major Barriers

Despite the availability of oncology data, privacy concerns continue to limit its effective use for research and collaboration.

Healthcare organizations today face a dual responsibility:

  1. Unlock data for innovation and research
  2. Protect patient identities and maintain regulatory compliance

Under GDPR, organizations must ensure that sensitive patient information cannot be re-identified or misused. This creates significant operational and legal complexity for hospitals, research institutions, and life sciences organizations working with oncology data.

Key barriers include:

  • patient identifiability risks
  • restrictions around secondary use of health data
  • lengthy legal and governance approval cycles
  • institutional concerns around liability and compliance

In many oncology data projects, the challenge is not the absence of data but the inability to share or use it safely.

Data Protection Officers (DPOs), governance teams, and ethics committees are now central stakeholders in research programs involving patient-level information. Poorly anonymized datasets can still contain hidden identifiers that increase the risk of re-identification, especially in oncology where rare disease combinations and longitudinal patient histories are common.

At the same time, patient trust has become increasingly important in the era of AI-driven healthcare. Patients understand that their data can help improve cancer research and accelerate innovation. But they also expect healthcare organizations to protect their privacy responsibly and transparently.

“In oncology data projects, the bottleneck is rarely data availability – it is trust and compliance.”

Why Oncology Data Is So Difficult to Anonymize

Oncology data presents unique anonymization challenges due to its complexity, richness, and dependence on unstructured clinical documentation. Unlike generic datasets, oncology records contain highly detailed narratives that describe disease progression, treatment responses, biomarkers, physician assessments, and multidisciplinary care decisions.

Much of this information exists in free-text clinical notes rather than standardized fields. Healthcare organizations must process a wide range of data formats, including:

  • Structured databases
  • Physician notes
  • Discharge summaries and epicrises
  • Pathology and radiology reports
  • Scanned PDFs
  • Image-associated metadata

Personally identifiable information (PII) may appear in unexpected locations throughout these records: names, dates, locations, physician references, rare disease descriptions, and contextual clues hidden in narrative text

The challenge becomes even greater in multinational European research environments where clinical records may exist in multiple languages. Traditional rule-based anonymization tools are rarely designed for:

  • oncology-specific terminology
  • multilingual clinical narratives
  • mixed-format medical records
  • AI-ready RWD workflows

As a result, they often miss hidden identifiers, require extensive manual review, reduce data utility, and fail to scale across institutions. Healthcare organizations are therefore forced to balance two competing priorities – protecting patient privacy and preserving research value. Over-anonymization can make datasets unusable for research. Under-anonymization increases governance and compliance risks.

“Generic anonymization tools break down when faced with real-world oncology data.”

How Danny Anonymization Works

Danny Anonymization was designed specifically to address the complexity of clinical oncology data environments. The platform transforms raw patient records into research-ready, de-identified datasets – automatically, intelligently, and irreversibly.

Step 1. Ingest Medical Records

Danny accepts structured data, scanned PDFs, or free-text clinical notes in multiple formats. This flexibility allows healthcare organizations to work with fragmented oncology data environments without requiring extensive preprocessing.

Step 2. AI-Based PII Recognition

Sqilline’s proprietary AI models to identify personally identifiable information not only in predefined fields but also hidden within free-text narratives such as physician comments, epicrises, pathology notes, and discharge summaries.

Unlike rule-based systems, the platform understands clinical context and medical language patterns, enabling accurate detection of contextual identifiers and oncology-specific terminology.

Step 3. Full One-Way Anonymization

The platform generates one-way irreversible hash keys to ensure patient identities can never be re-linked or recovered. This creates secure secondary use environments, strong privacy protection, trusted research datasets, and compliance-ready outputs.

Step 4. GDPR-Certified Output

Anonymized datasets are fully compliant and ready for secure sharing, RWD platforms, or internal research.Top of FormBottom of Form Importantly, the anonymization process preserves analytical value while eliminating patient exposure risks.

“From raw EHRs to anonymized datasets – fully automated and clinically aware.”

Key Capabilities of Danny Anonymization

AI-Based PII Detection

Danny automatically detects and removes names, dates, addresses, phone numbers, and contextual identifiers across both structured and unstructured clinical data.

Multilingual Support

The platform supports anonymization across 11 European languages, enabling secure multinational oncology projects and cross-border RWE initiatives.

Compliance-Ready Outputs

Built-in governance capabilities include anonymization traceability, workflow transparency, governance-ready reporting, and auditability support. The platform generates logs and audit trails that support governance teams and Data Protection Officers.

Automation & Scalability

Danny replaces weeks of manual anonymization review with scalable automated workflows. It helps organizations reduce operational overhead, accelerate research readiness, standardize anonymization processes, and scale securely across institutions and datasets.

The solution can operate as a standalone solution or part of the broader Danny Platform.

Security by Design

Danny uses a privacy-first architecture specifically designed for sensitive healthcare environments. Its irreversible hash generation model ensures permanent de-identification, zero re-linking risk, and secure secondary use of oncology data.

AI models are only as valuable as the quality, accessibility, and privacy-readiness of the data behind them. Clinical-grade anonymization is therefore becoming foundational infrastructure for trustworthy healthcare AI.

“Clinical-grade anonymization requires more than masking – it requires intelligence, scale, and compliance by design.”

Real-World Use Cases

Hospitals, Cancer Centers & Research Networks

Healthcare organizations can use Danny to anonymize patient-level oncology data for internal analyses, clinical audits, treatment pathway optimization, outcomes tracking, and quality improvement initiatives without triggering complex manual anonymization workflows.

Danny also enables secure collaboration between hospitals, cancer centers, academic institutions, and national research networks while fully protecting patient identities.

By automating anonymization workflows, healthcare organizations can better align with institutional governance requirements while reducing the operational burden on compliance teams.

Pharma & Life Sciences

For life sciences organizations, Danny enables compliant access to hospital-sourced oncology RWD that can support feasibility studies, clinical trial design, observational research, real-world evidence generation, and post-market surveillance without exposure to patient identifiers.

Anonymized datasets can also accelerate HTA submissions, reimbursement frameworks, regulatory evidence generation, and patient access strategies.

By minimizing legal and governance concerns around patient data exposure, Danny helps speed up partnerships between hospitals, pharma industry, CROs, institutions and research organizations.

“Anonymization transforms isolated datasets into collaborative research assets.”

The Danny Platform Approach

Anonymization is only one part of the oncology data journey. The broader Danny Platform enables healthcare organizations to move seamlessly from fragmented raw data to actionable clinical and business insights.

End-to-End Oncology Data Workflow

Raw Oncology Data
↓
Danny Anonymization
↓
Danny DataStruct
↓
Danny Analytics
↓
Danny FindMore
↓
Danny DecisionSupport

Danny Anonymization

Protects patient privacy and enables compliant secondary use.

Danny DataStruct

Transforms fragmented oncology records into standardized research-ready datasets.

Danny Analytics

Generates operational insights, real-world evidence, and clinical intelligence.

Danny FindMore

Accelerates clinical trial feasibility and recruitment.

Danny DecisionSupport

Supports advanced clinical and analytical decision-making workflows.

Together, these components create an integrated oncology data infrastructure built for privacy-preserving research, AI-driven analytics, cross-institutional collaboration, and scalable evidence generation.

“The future of oncology research depends on our ability to make sensitive clinical data usable without compromising patient trust or regulatory integrity.” – Mihail Zhekov, CTO, Sqilline Health.

The Future of Privacy-Preserving Oncology Research

The future of oncology research will increasingly depend on the ability to combine AI, real-world evidence, cross-border collaboration, and trusted data ecosystems. Across Europe, initiatives such as the European Health Data Space (EHDS) are accelerating the secondary use of healthcare data for research and innovation. As these ecosystems evolve, privacy-preserving infrastructure will become essential for every healthcare organization participating in data-driven oncology research.

Clinical-grade anonymization will play a foundational role in AI training, trusted research environments, multinational oncology studies, secure data collaboration, and scalable healthcare innovation. Organizations that can securely transform sensitive clinical records into research-ready datasets will be best positioned to drive the next generation of oncology innovation.

“The future of oncology research depends on the ability to use data without compromising patient trust.”

Unlock the Value of Oncology Data Securely and Responsibly

Clinical-grade anonymization is no longer a compliance checkbox. It is the foundation of scalable, trustworthy oncology real-world evidence.